MyBlog

As we all know, DIWALI is nearby....

Through this blog our me and my team members are wishing all the readers of Pharmainfo.net a very HAPPY DIWALI...!

Shubham Karoti Kalyanam,

Arogram Dhana Sampada,

Shatru Buddhi Vinashay, Deepamjyoti Namostute...!

Iontophoresis describes the technique whereby electrically charged molecules are moved across the skin by repulsive electromotive force. Vyteris has demonstrated successful delivery of peptides up to 3.5kDa

Altea Therapeutics is developing a transdermal patch with applications in delivering insulin, fentanyl citrate and a range of vaccines

A range of techniques has evolved aimed at increasing the skin’s permeability without irreversibly
changing barrier function

Chemical penetration enhancers:
Surfactants – fatty acids, fatty esters alter the structure of the stratum corneum. But they are not selective for intercellular lipids and also affect membrane lipids of epidermal cells and induce irritation

Influenza A (H1N1) 2009 Monovalent Vaccine is developed by Novartis Vaccines and Diagnostics Ltd. Given as suspension for Intramuscular Injection

INDICATIONS AND USAGE
• Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 4 years of age and older against influenza disease caused by pandemic (H1N1) 2009 virus

Pharmaceutical Product Development:

Objectives:

1.Provide a continuous link from early phase characterization to final manufacturing process- Process Development is the link through all these phases

2.Define process based on unit operations approach-Unit Operations define the building blocks of the process.

The total number of drug delivery deals has increased steadily in recent years, exceeding 330 in 2007, approximately 12% of all pharma deals
This increase has been driven by a sharp rise in the number of drug delivery licensing deals between biotech and big pharma. The number of deals reached 153 in 2007, up from 63 in 1997.

A good example of a drug delivery technology that has disrupted the established
market place is the arrival of drug-eluting stents (DES) in 2002 for the treatment of
coronary artery disease. The build up of plaque on coronary arteries (atherosclerosis)
can eventually lead to partial or complete closure of these vessels and result in
infarction to the surrounding tissue

Ustekinumab Injection

Date of Approval: September 25, 2009

Company: Centocor Ortho Biotech Inc.

Treatment for: Psoriasis

Stelara (ustekinumab) is a human monoclonal antibody for the treatment of moderate to severe plaque psoriasis.